Diabetes Mellitus Clinical Trial
Official title:
Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention
The main objective of this study is to assess the safety, efficacy and dose response of
LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI)
with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography
(OCT) at 9 months post procedure in patients with diabetes mellitus (DM).
Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as
assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in
patients with DM.
This is a phase IIb, prospective, multi-center, multi-national, randomized, double-blind,
two-arm, 1:1 (escalating dose LABR-312 vs. placebo) clinical trial.
In both study arms, all target lesions will be treated with the Resolute Integrity Drug
Eluting Stent during the index PCI.
Lesions that are planned to be treated must be declared and recorded at the time of
randomization.
Randomization will be stratified by the presence or absence of insulin treatment, HbA1c level
(<7.5% vs. ≥7.5%), and by pre-procedure monocyte count (≥500/uL or below).
Subjects (n=~270) will be randomized to receive either the study drug LABR-312 or the
placebo. Conditionally to ongoing safety monitoring, dose escalation of LABR-312 in the study
arm will be performed: 0.01 mg (first 45 patients vs. 45 patients receiving placebo), up to
0.03 mg (next consecutive 45 patients vs. 45 patients receiving placebo) and up to 0.08 mg
(final 45 consecutive patients vs. 45 patients receiving placebo). If a decision is made not
to dose escalate, recruitment will continue with the highest dose level deemed safe by the
ongoing safety monitoring, until approximately 270 subjects are randomized.
In the LABR-312 group, 3 doses will therefore be tested, resulting in 6 possibilities:
Group 1: Low dose 0.01 mg LABR-312 or equivalent volume of placebo (saline) administered IV.
Group 2: Intermediate dose Up to 0.03 mg LABR-312 or equivalent volume of placebo (saline)
administered IV.
Group 3: High dose Up to 0.08 mg LABR-312 or equivalent volume of placebo (saline)
administered IV.
The duration of subject participation will be 1 year; clinical follow-up will be performed at
30 days, 9 months, and 1year post randomization.
OCT follow-up will be performed at 9 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |